U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07835880) titled '[18F]FIDT-10b PET Imaging in Cardiac Amyloidosis' on Sept. 17.
Brief Summary: This is a first in human study that will assess the safety, pharmacokinetics, biodistribution and diagnostic performance of [18F]FIDT-10b (fluorine-18 labeled FIDT-10b), a positron emission tomography (PET) agent. This agent has the potential to specifically identify the involved myocardium of patients with transthyretin cardiac amyloidosis (ATTR-CA).
Study Start Date: Aug. 31
Study Type: INTERVENTIONAL
Condition:
Transthyretin Cardiac Amyloidosis
Light Chain Cardiac Amyloidosis
Intervention:
DRUG: [18F]FIDT-10b
An I.V. bolus injection of up to 10 ...